MARKET WIREReuters • 2h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
Why ZLAB Stock dropped -2.95% Today — RQD Quant Desk Flash
$22.36 -2.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $22.20
Zai Lab Limited (ZLAB) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $2.51B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ZLAB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ZLAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Zai Lab Limited (NASDAQ: ZLAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $22.36 (-2.95% 1D, market cap $2.51B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ZLAB ranks #983 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ZLAB compare to BHVN and NAMS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZLAB carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 58.3%, and ROIC of -35.0%. By comparison, BHVN (Biohaven Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $2.49B) and NAMS (NewAmsterdam Pharma Company N.V.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $2.48B). Among the 5-stock peer group, ZLAB leads on earnings multiple (N/A) while SUPN leads on capital efficiency (-4.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ZLAB?
▼
Per ZLAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001704292), Zai Lab Limited generated $457.2M in revenue (+15.0% YoY), -$175.5M in net income, and -$158.9M in free cash flow against $1.17B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $22.20 (-0.72%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-14.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZLAB)Realized 20D OHLCV Swing Band: ±10.7%
Deterministic 5-Pillar Attribution (26/100 Composite)
🔍 WHY ZLAB SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (31% of score)
Altman Z-Score 0.52 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
▲ #2 Bullish Driver: Whale & Options Positioning+6/20 pts (23% of score)
20D Institutional Volume Accumulation (±10.7% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$24.99-7.2% Next Q
34
Q2 (-2Q)Grade E$23.19+3.6% Next Q
31
Q3 (-1Q)Grade E$24.03-6.9% Next Q
29
CurrentGrade E$22.36-10.5% Hist 90D α
26
Trajectory: E (34) → E (26)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ZLAB Turnaround Squeeze
While ZLAB currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.94) and Max Pain ($23.48) forces dealer call-delta covering toward $28.88.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZLAB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ZLAB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ZLAB Stock dropped -2.95% Today — RQD Quant Desk Flash
Zai Lab Limited (ZLAB) dropped -2.95% to $22.36, trading at 55% of its 52-week range ($15.96 – $27.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 55% of its 52-week range ($15.96 – $27.5) with RSI-14 at 40.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.7% around $22.36 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 58.3% gross margin and $0 annual free cash flow.
Live ZLAB Headlines & Catalysts
MARKET WIREReuters • 3h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 5h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 7h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 7h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 8h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 9h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 10h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZLAB)
- ✓Walkthrough of ZLAB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ZLAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3.33%📐 WEDGE COMPRESSION COIL
2026-10-30O $22.30H $22.42L $21.80C $22.36VOL 637.8K
RES: $26.60SUP: $21.00SMA50: $24.94SMA200: $20.98
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ZLAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +15.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ZLAB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ZLAB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ZLAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZLAB)
Health Care Rank #983 of 1016
⚔️ BHVN vs ZLAB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ZLAB vs. BHVN, NAMS, SUPN, MBX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Zai Lab Limited (ZLAB) ranks #983 by composite RQD confidence (26/100, grade E) and #220 by equity capitalization ($2.51B). Within this direct 5-issuer industry benchmark cohort, ZLAB leads on earnings valuation at N/A trailing P/E, while SUPN leads on capital efficiency and profitability with -4.5% ROIC and 89.6% gross margin. SUPN currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with ZLAB at 26/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ZLAB
ACTIVE
Zai Lab Limited | E | 26/100 | — | 58.3% | -35.0% | -2.95% | $2.51B | Benchmark Subject |
| BHVN Biohaven Ltd. | D | 46/100 | — | — | -35.0% | +6.25% | $2.49B | /bhvn-vs-zlab → |
| NAMS NewAmsterdam Pharma Company N.V. | D- | 38/100 | — | — | -35.0% | -1.47% | $2.48B | /nams-vs-zlab → |
| SUPN Supernus Pharmaceuticals Inc. | D+ | 56/100 | — | 89.6% | -4.5% | +1.85% | $2.43B | /supn-vs-zlab → |
| MBX MBX Biosciences Inc. | D | 44/100 | — | — | -26.4% | +0.70% | $2.63B | /mbx-vs-zlab → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001704292In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zai Lab Limited (ZLAB) reported GAAP revenue of $457.2M (+15.0% vs. FY2024 revenue of $397.6M , and +71.4% cumulative change since FY2023) , GAAP net income of -$175.5M, operating cash flow of -$150.8M, and free cash flow of -$158.9M (+27.9% YoY). On the balance sheet, ZLAB closed FY2025 with $1.17B in total assets against $0 in total debt (Altman Z-Score: 0.52, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $457.2M | -$175.5M | -$150.8M | -$158.9M | $1.17B | — |
| FY2024 (FY) | 2024-12-31 | $397.6M | -$257.1M | -$214.9M | -$220.5M | $1.19B | — |
| FY2023 (FY) | 2023-12-31 | $266.7M | -$334.6M | -$198.2M | -$198.2M | — | — |
3. ZLAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ZLAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Zai Lab Limited (NASDAQ: ZLAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $22.36 (-2.95% 1D, market cap $2.51B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ZLAB ranks #983 in composite RQD confidence.
How does ZLAB compare to BHVN and NAMS in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZLAB carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 58.3%, and ROIC of -35.0%. By comparison, BHVN (Biohaven Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $2.49B) and NAMS (NewAmsterdam Pharma Company N.V.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $2.48B). Among the 5-stock peer group, ZLAB leads on earnings multiple (N/A) while SUPN leads on capital efficiency (-4.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ZLAB?
Per ZLAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001704292), Zai Lab Limited generated $457.2M in revenue (+15.0% YoY), -$175.5M in net income, and -$158.9M in free cash flow against $1.17B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ZLAB trading relative to its 50-day, 200-day, and 52-week technical levels?
ZLAB last traded at $22.36 (-2.95% on volume of 648,529 shares), positioning the stock -10.34% below its 50-day simple moving average ($24.94) and +6.58% above its 200-day simple moving average ($20.98). Across its 52-week range of $15.96 to $27.50, ZLAB sits at the 55.5% percentile with a 14-day RSI of 40.3 (NEUTRAL RANGE) and an implied next-earnings move of ±10.7% ($19.97 to $24.75).
ZLAB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ZLAB stock moving today?
Why ZLAB Stock dropped -2.95% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.